| Literature DB >> 22098833 |
Abstract
To optimize the therapeutic value of an operation for cancer, surgeons must weigh survival value against mortality/morbidity risk. As a result of several prospective, randomized trials, many surgeons feel that international opinion has reached a consensus. Reflexively radical surgical hubris has certainly given way to a more nuanced, customized approach to this disease. But issues remain. This article critically reviews existing data and emphasizes areas of continued controversy. Published by Elsevier Inc.Entities:
Mesh:
Year: 2012 PMID: 22098833 DOI: 10.1016/j.soc.2011.09.005
Source DB: PubMed Journal: Surg Oncol Clin N Am ISSN: 1055-3207 Impact factor: 3.495